Methods and findings in experimental and clinical pharmacology最新文献_第2页

[Treatment of chronic graft-versus-host disease with protein tyrosine kinase inhibitors]. 蛋白酪氨酸激酶抑制剂治疗慢性移植物抗宿主病

Methods and findings in experimental and clinical pharmacology Pub Date : 2010-12-01

C Martínez

引用次数: 0

[Clinical impact of HLA disparities in transplants from unrelated donors]. 【非亲属供体移植中HLA差异的临床影响】。

Methods and findings in experimental and clinical pharmacology Pub Date : 2010-12-01

D Gallardo

引用次数: 0

[The use of oncolytic adenovirus for the treatment of cancer]. [利用溶瘤腺病毒治疗癌症]。

Methods and findings in experimental and clinical pharmacology Pub Date : 2010-12-01

M Cascalló

引用次数: 0

[Pegfilgrastim in hematopoietic stem cell transplantation]. 聚非格拉西汀在造血干细胞移植中的应用

Methods and findings in experimental and clinical pharmacology Pub Date : 2010-12-01

R Fernández Alvarez

引用次数: 0

Inhibitory effect of hydrocortisone on cerebral salt wasting after subarachnoid hemorrhage in rats. 氢化可的松对大鼠蛛网膜下腔出血后脑盐消耗的抑制作用。

Methods and findings in experimental and clinical pharmacology Pub Date : 2010-12-01 DOI: 10.1358/mf.2010.32.10.1561078

M Yoneko, Y Katayama, N Moro, J Kamei, J Kojima

引用次数: 3

[Association between genetic polymorphism in the promotor region of CD209 and propensity to develop invasive pulmonary aspergillosis]. [CD209启动子区基因多态性与侵袭性肺曲霉病发病倾向的关系]。

Methods and findings in experimental and clinical pharmacology Pub Date : 2010-12-01

J Sainz, J Segura-Catena, M Jurado

{"title":"[Association between genetic polymorphism in the promotor region of CD209 and propensity to develop invasive pulmonary aspergillosis].","authors":"J Sainz, J Segura-Catena, M Jurado","doi":"","DOIUrl":"","url":null,"abstract":"Fungi of the genus Aspergillus are found everywhere in the natural environment; they cause invasive pulmonary aspergillosis (IPA), an infectious complication common in immunocompromised individuals, which has a mortality rate of up to 90% in patients with hematological malignancy. The first line of defense of innate immunity is the recognition of Aspergillus conidia by dendritic cells or alveolar macrophages. DC-SIGN is an integrin directly involved in this recognition; its degree of expression in immune cells and its functionality may be partly determined by genetic variations. The objective of this study was to determine whether the presence of polymorphisms of a single nucleotide in the DC-SIGN gene increases the risk of invasive pulmonary aspergillosis. For this purpose, the variants DC-SIGN-139A/G (rs2287886) and DC-SIGN+11C/G (rs7252229) were analyzed In 314 subjects (152 patients with hematologic malignancy and 162 healthy controls). Of the 152 hematologic cancer patients, 81 were diagnosed with demonstrated invasive pulmonary aspergillosis per EORTC/IFICG criteria, and the remaining 71 patients had no symptoms of the infection. An association was found between the variant DC-SIGN-139(A/G) and resistance to IPA. Carriers of the allele A (A/A + A/G) were significantly more resistant to the infection than patients with the G/G genotype (p = 0.0574). Analysis of the serum concentration of the galactomannan antigen supported the hypothesis that this polymorphism may be implicated in the susceptibility to suffer invasive pulmonary aspergillosis. Although the difference was not statistically significant, carriers of the allele G had a higher frequency of positive galactomannans than subjects with the genotype A/A (p = 0.1921). These results suggest that the variant DC-SIGN-139(A/G) in the DC-SIGN gene promoter influences the risk of invasive pulmonary aspergillosis and may therefore be used as a genetic biomarker to stratify patients according to risk.","PeriodicalId":18443,"journal":{"name":"Methods and findings in experimental and clinical pharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2010-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29721626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Romiplostim: an advance in the treatment of idiopathic thrombocytopenic purpura]. [Romiplostim:特发性血小板减少性紫癜的治疗进展]。

Methods and findings in experimental and clinical pharmacology Pub Date : 2010-12-01

M E Mingot Castellano

{"title":"[Romiplostim: an advance in the treatment of idiopathic thrombocytopenic purpura].","authors":"M E Mingot Castellano","doi":"","DOIUrl":"","url":null,"abstract":"Primary Immune thrombocytopenia or idiopathic thrombocytopenic purpura (ITP) is an acquired immune disorder presenting with abnormal hemorrhagic symptoms resulting from a decrease in the number of platelets. The disorder used to be attributed to increased destruction of platelets mediated by antibodies. In the past few years, the description of its etiopathology has changed. A deficiency in the marrow production of thrombocytes has been demonstrated; because it is associated with increased peripheral platelet destruction, the deficiency cannot be compensated. These findings have justified the realization of studies assessing the utility of second generation thrombopoietin analogues for the treatment of these patients. These drugs include romiplostim or AMG 537 (Nplate), a peptidic analogue that stimulates the thrombopoietin receptor and induces an increase In the production and differentiation of megakaryocytes. Data obtained from the clinical trials that led to the authorization and subsequent follow-up describe romiplostin as an effective and safe drug for adult patients with chronic ITR The overall response rate is 94%; despite variations in the levels of platelets throughout treatment, 50% of patients maintain the response 95% of the time, and 78% of patients discontinue or significantly reduce the use of rescue treatment. The most common adverse event is headache. Reticulin fibrosis has been described, which is reversible after treatment discontinuation.","PeriodicalId":18443,"journal":{"name":"Methods and findings in experimental and clinical pharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2010-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29721631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Valeriana jatamansi partially reverses liver cirrhosis and tissue hyperproliferative response in rat. 缬草部分逆转大鼠肝硬化和组织增生性反应。

Methods and findings in experimental and clinical pharmacology Pub Date : 2010-12-01 DOI: 10.1358/mf.2010.32.10.1522224

R Prasad, M Naime, I Routray, A Mahmood, F Khan, S Ali

引用次数: 12

Innervation of histamine neurons in the caudal part of the arcuate nucleus of hypothalamus and their activation in response to food deprivation under scheduled feeding. 下丘脑弓状核尾部组胺神经元的神经支配及其在计划进食条件下对食物剥夺的反应。

Methods and findings in experimental and clinical pharmacology Pub Date : 2010-12-01 DOI: 10.1358/mf.2010.32.10.1545781

H Umehara, H Mizuguchi, N Mizukawa, M Matsumoto, N Takeda, E Senba, H Fukui

{"title":"Innervation of histamine neurons in the caudal part of the arcuate nucleus of hypothalamus and their activation in response to food deprivation under scheduled feeding.","authors":"H Umehara, H Mizuguchi, N Mizukawa, M Matsumoto, N Takeda, E Senba, H Fukui","doi":"10.1358/mf.2010.32.10.1545781","DOIUrl":"https://doi.org/10.1358/mf.2010.32.10.1545781","url":null,"abstract":"It has been well established that histaminergic neurons innervate densely the anterior hypothalamus and regulate several functions through the histamine H₁ receptor (H1R). However, the physiological function of the histaminergic neurons in other regions including the posterior hypothalamus has not been fully investigated. Recently, we have found a selective c-Fos expression in the caudal part of the arcuate nucleus of the hypothalamus (cARC) by food deprivation under scheduled feeding in rats. In this study, we histochemically examined the correlation of this c-Fos expression with the activation of histaminergic neurons in this region using an anti-H1R antibody. Strong H1R immunoreactivity was observed in the perikarya of the c-Fos positive cells. Abundant histamine-containing fibers were also found in the cARC and in the area between the cARC and the tuberomammillary nucleus (TM), where the histaminergic neuronal cell bodies are exclusively distributed. Our morphological observations suggest that c-Fos expression in the cARC by food deprivation under scheduled feeding is caused by the activation of histaminergic neurons projected from the TM.","PeriodicalId":18443,"journal":{"name":"Methods and findings in experimental and clinical pharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2010-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29590004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 12

[Treatment algorithm for gastrointestinal graft-versus-host disease]. [胃肠道移植物抗宿主病的治疗算法]。

Methods and findings in experimental and clinical pharmacology Pub Date : 2010-12-01

G B McDonald

{"title":"[Treatment algorithm for gastrointestinal graft-versus-host disease].","authors":"G B McDonald","doi":"","DOIUrl":"","url":null,"abstract":"Over the last decade, there has been a dramatic decline in the frequency of organ failure, infection, and severe acute CVHD as causes of non-relapse mortality after allogeneic hematopoietic cell transplantation. Gastrointestinal CVHD, however, remains a significant obstacle to survival. Patients who present with non-progressive symptoms of the upper gut phenotype of GVHD seldom progress to severe CVHD, but may have a prolonged course, they can be successfully treated with prednisone 1 mg/kg/day for a limited time, along with topical and oral glucocorticoid. Patients who present with the mid-gut phenotype of GVHD can be recognized soon after presentation by secretory protein-losing enteropathy and falling serum albumin; their treatment requires prednisone 2 mg/kg/day and probably an additional drug such as mycophenolic acid. Failure to improve identifies a cohort with a poor prognosis; secondary therapy should be started while gut mucosa is still intact, but no secondary therapies have been proven in randomized trials to improve survival. Patients whose initial presentation (large volume diarrhea, low serum albumin, jaundice, mucosal necrosis and sloughing at initial endoscopy) presages a fatal outcome have not been studied prospectively.","PeriodicalId":18443,"journal":{"name":"Methods and findings in experimental and clinical pharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2010-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29721532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0